I'd buy CBA and BHP shares. But I'd buy this ASX blue chip first

Two of Australia's biggest companies would be on my buy list, but there's another share I'd put ahead of both.

There are a handful of ASX blue chips I'd be comfortable owning for the next decade.

Two familiar names are high on that list. But there's another business I'd put ahead of both, largely because I think investors could be underestimating how much room it has to grow.

Mid-aged couple looking at a laptop.

Image source: Getty Images

Why I'd buy CBA and BHP shares

I remain a fan of Commonwealth Bank of Australia (ASX: CBA).

Its enormous customer base, leading digital banking services, and strength in deposits give it advantages that competitors have spent years trying to match.

And its latest quarterly update showed that the bank is still growing lending while maintaining a broadly stable underlying interest margin.

I'd also happily own BHP Group Ltd (ASX: BHP) shares.

Its iron ore business generates significant cash flow, while copper and the emerging potash business could become bigger earnings contributors over time.

BHP will always be exposed to commodity cycles, but I like having several ways to benefit from global demand for resources.

So why would I put another company first?

The blue chip I'd choose

My pick is ResMed Inc (ASX: RMD), the sleep health technology company.

The biggest reason I'd favour it is the extraordinary number of people who could benefit from its products but aren't receiving treatment.

According to ResMed's investor presentations, more than one billion people worldwide are estimated to have sleep apnoea.

Yet fewer than 20% of affected people in the US, and fewer than 10% elsewhere, have been diagnosed or treated. I think that's an enormous long-term opportunity.

And developments in technology could help ResMed reach more of these people.

For example, its partnership with the wearable technology company ŌURA helps users recognise potential sleep-breathing problems and connect them with sleep assessments and treatment information.

I believe growing awareness could encourage millions more people to seek diagnosis and treatment over the coming decade.

Why Ozempic might be good news

Another reason I'm positive is the growing popularity of weight-loss drugs such as Ozempic.

Initially, investors worried that these medicines could reduce demand for ResMed's sleep apnoea machines.

After all, weight loss can improve the condition for some patients.

However, there's emerging evidence suggesting these drugs could also benefit ResMed.

In its latest presentation, the company highlighted an analysis involving 3.3 million patients.

It found that patients prescribed GLP-1 drugs were more likely to begin positive airway pressure therapy and had higher replacement-supply rates than those not prescribed the drugs.

Although this doesn't prove the drugs caused greater treatment uptake, I think it challenges the assumption that their growing popularity will hurt ResMed.

And once patients begin treatment, ResMed can generate ongoing revenue from replacement masks and accessories.

The growth outlook

ResMed's ambitions are also encouraging. Management is targeting high-single-digit annual revenue growth over its five-year outlook to 2030, with earnings expected to grow faster than sales.

And its latest quarterly results suggest it's making progress. Core revenue increased 7% in constant currency, while adjusted earnings per share (EPS) rose 14%.

I believe the combination of an enormous underserved market, greater awareness, and continued product innovation could support this growth for many years.

Competition from alternative treatments and changes in healthcare reimbursement remain risks, but I'm optimistic about the company's future.

Foolish takeaway

I think CBA and BHP are excellent shares, and I'd happily own either.

However, ResMed's long-term growth opportunity looks even stronger to me.

With so many people still undiagnosed and management targeting faster earnings growth, it would be my first choice of the three today.

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Happy businessman fist pumping while looking at a tablet.
Blue Chip Shares

Why I'm not buying CBA shares but would sell everything to buy one ASX stock

I think this stock could outperform the big four bank.

Read more »

Woman using her laptop with her feet up.
Blue Chip Shares

Which ASX 200 share would I buy with $10,000 today?

I think investors could be overlooking some of the ways this business can keep growing its earnings.

Read more »

Couple on their laptop in their home kitchen.
Blue Chip Shares

I'd rather buy these 3 ASX shares than Commonwealth Bank

I'm a big fan of the banking giant but not its valuation.

Read more »

A man and woman watch their device screens, making investing decisions at home.
Blue Chip Shares

If I could choose only one, would I buy Telstra or Wesfarmers shares?

I like both businesses, but if I could only add one to my portfolio today, there's a clear reason behind…

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Blue Chip Shares

Why I'd buy Wesfarmers and Coles shares today

These businesses aren't trading at bargain prices, but I think their long-term opportunities justify a closer look.

Read more »

Happy young couple riding a motorbike together.
Blue Chip Shares

Why I'd buy these ASX blue-chip shares until at least 2036

I'm looking at three established businesses that could become more profitable over the next 10 years.

Read more »

Blue chips with stock written on them.
Blue Chip Shares

2 ASX blue-chip shares offering large dividend yields

I think these businesses have a very compelling future.

Read more »

Three smiling corporate people examine a model of a new building complex.
Blue Chip Shares

3 popular ASX shares I'd happily buy and hold until 2036

Wondering where to invest for the long term? I have my eyes on these shares.

Read more »